P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort.
暂无分享,去创建一个
T. Molnár | M. Papp | P. Lakatos | B. Gasztonyi | Z. Szepes | P. Miheller | J. Banai | B. Szalay | K. Gecse | L. Lakatos | K. Palatka | T. Szamosi | Á. Patai | Z. Végh | Á. Vincze | K. Farkas | M. Rutka | Á. Salamon | P. Golovics | B. Lovász | L. Gonczi | G. Tóth | L. Bene | T. Kristof | Z. Kurti